Pemphigus Vulgaris - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Pemphigus Vulgaris - Pipeline Review, H1 2016', provides an overview of the Pemphigus Vulgaris pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris - The report reviews pipeline therapeutics for Pemphigus Vulgaris by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Pemphigus Vulgaris therapeutics and enlists all their major and minor projects - The report assesses Pemphigus Vulgaris therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pemphigus Vulgaris - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pemphigus Vulgaris pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Pemphigus Vulgaris Overview 6 Therapeutics Development 7 Pipeline Products for Pemphigus Vulgaris - Overview 7 Pipeline Products for Pemphigus Vulgaris - Comparative Analysis 8 Pemphigus Vulgaris - Therapeutics under Development by Companies 9 Pemphigus Vulgaris - Therapeutics under Investigation by Universities/Institutes 10 Pemphigus Vulgaris - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Pemphigus Vulgaris - Products under Development by Companies 15 Pemphigus Vulgaris - Products under Investigation by Universities/Institutes 16 Pemphigus Vulgaris - Companies Involved in Therapeutics Development 17 Almirall, S.A. 17 Biogen, Inc. 18 F. Hoffmann-La Roche Ltd. 19 HanAll Biopharma Co., Ltd. 20 Immunomedics, Inc. 21 Novartis AG 22 Principia Biopharma Inc. 23 Pemphigus Vulgaris - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 ADP-31415 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 DPC-006 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 HL-161 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 mycophenolate mofetil - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 PRN-1008 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 rituximab - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 VAY-736 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 veltuzumab - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Pemphigus Vulgaris - Recent Pipeline Updates 49 Pemphigus Vulgaris - Dormant Projects 54 Pemphigus Vulgaris - Discontinued Products 55 Pemphigus Vulgaris - Product Development Milestones 56 Featured News & Press Releases 56 Jan 07, 2016: Principia Biopharma Advances BTK Inhibitor Program in Autoimmune Disease and FGFR Inhibitor Program in Oncology 56 Aug 25, 2015: Genentech Initiates Phase III Trial of Rituxan for Rare, Autoimmune Disease: Pemphigus Vulgaris 56 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 58 Disclaimer 59
List of Tables
Number of Products under Development for Pemphigus Vulgaris, H1 2016 7 Number of Products under Development for Pemphigus Vulgaris - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Comparative Analysis by Unknown Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Pemphigus Vulgaris - Pipeline by Almirall, S.A., H1 2016 17 Pemphigus Vulgaris - Pipeline by Biogen, Inc., H1 2016 18 Pemphigus Vulgaris - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 19 Pemphigus Vulgaris - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 20 Pemphigus Vulgaris - Pipeline by Immunomedics, Inc., H1 2016 21 Pemphigus Vulgaris - Pipeline by Novartis AG, H1 2016 22 Pemphigus Vulgaris - Pipeline by Principia Biopharma Inc., H1 2016 23 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Stage and Target, H1 2016 26 Number of Products by Stage and Mechanism of Action, H1 2016 28 Number of Products by Stage and Route of Administration, H1 2016 30 Number of Products by Stage and Molecule Type, H1 2016 32 Pemphigus Vulgaris Therapeutics - Recent Pipeline Updates, H1 2016 49 Pemphigus Vulgaris - Dormant Projects, H1 2016 54 Pemphigus Vulgaris - Discontinued Products, H1 2016 55
List of Figures
Number of Products under Development for Pemphigus Vulgaris, H1 2016 7 Number of Products under Development for Pemphigus Vulgaris - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Early Stage Products, H1 2016 13 Assessment by Monotherapy Products, H1 2016 24 Number of Products by Targets, H1 2016 25 Number of Products by Stage and Targets, H1 2016 25 Number of Products by Mechanism of Actions, H1 2016 27 Number of Products by Stage and Mechanism of Actions, H1 2016 27 Number of Products by Routes of Administration, H1 2016 29 Number of Products by Stage and Routes of Administration, H1 2016 29 Number of Products by Molecule Types, H1 2016 31 Number of Products by Stage and Molecule Types, H1 2016 31
Global FPGA market is anticipated to be valued at USD 9,882.5 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing demand for customized IC’s is expected to drive the demand. Customized IC’s helps manufacturers to moRead More...
Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to driveRead More...
Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing apRead More...
Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growtRead More...
Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous industRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.